Back to results
US 10,557,170 B2Granted
Thromboembolic disease markers
AssigneeGendiag.exe, S.L.
InventorsEduardo Salas, José Manuel Soria, Miroslava Ogorelkova, Roberto Elosua Llanos, Joan Vila, Sergio Castillo Fernandez
Life of this patent
Estimating the term…
Abstract
The invention relates to a method for a more appropriate thromboembolic event risk assessment based on the presence of different genetic variant. The invention also relates to a method for determining the risk of suffering a thromboembolism disease by combining the absence or presence of one or more polymorphic markers in a sample from the subject with conventional risk factors for thromboembolism as well as computer-implemented means for carrying out said method.
Claims13
A method comprising:
- a) determining in a sample isolated from a human subject the presence or absence of each of the following polymorphisms:
- Serpin A10 (protein Z inhibitor) Arg67Stop (rs2232698),
- Serpin CI (antithrombin) Ala384Ser (Cambridge II),
- factor XIIC46T (rsl801020),
- factor XIII Va134Leu (rs5985),
- Factor II (prothrombin) G20210A (rsl799963),
- factor V Leiden Arg506Gln (rs6025),
- factor V Cambridge Arg306Thr,
- factor V Hong Kong Arg306Gly,
- ABO blood group rs8176719,
- ABO blood group rs7853989,
- ABO blood group rs8176743, and
- ABO blood group rs8176750;
- b) detecting the presence of at least one of said polymorphisms in said subject;
- c) identifying the subject with at least one of said polymorphisms for treatment and
- d) administering to the subject identified in step c) an anticoagulant and/or antithrombotic therapy.
13 more elements
Dependencies are inferred from the claim text.